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 CASE REPORT 
 
A case report of drug rash with eosinophilia and systemic symptoms in a 
patient using carbamazepine 
 











Drug rash with eosinophilia and systemic symptoms (DRESS) is a critical type of drug reaction with 
signs such as fever, skin rash, lymphadenopathy, hematological abnormalities particularly 
eosinophilia, and internal organ involvement like hepatitis two to eight weeks after a drug is first 
used. The present case is an example of hepatitis as a manifestation of drug reaction with eosinophilia 
and systemic symptoms syndrome.  
 
Case Presentation  
A 17 year-old man is reported as a known case of epilepsy from childhood, who presented anti-
epileptic-induced “drug reaction with eosinophilia and systemic symptoms syndrome” with a seven-
day history of pruritic rash, periorbital, face and upper extremities edema, hepatitis and fever was 
admitted at Loghman Hakim Hospital in Tehran, Iran in December, 2015. Laboratory tests showed an 
eosinophilia and elevated serum liver enzymes. The patient's history showed no drug allergies, but 
five weeks prior to hospital admission, his therapy regimen had been changed from sodium-valproate 
to carbamazepine. Carbamazepine was discontinued on hospital admission, and after nine days of 
high-dose corticosteroid therapy the patient's symptoms and laboratory markers were stable.  
 
Conclusion  
Given the high morbidity and mortality rate of DRESS syndrome, physicians should bear in mind this 
severe hypersensitivity reaction particularly when starting anti-epileptic drugs. Early diagnosis of 
drug reaction with eosinophilia and systemic symptoms syndrome and initiation of appropriate 
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Introduction  
Bocquet and colleagues in 1996 first presented 
drug reaction with eosinophilia and systemic 
symptoms (DRESS). The clinical 
manifestations include an extensive rash, 
fever, lymphadenopathy, hematologic 
disorders like eosinophilia or atypical 
lymphocytes, hepatitis, and involvement of 
other internal organs like kidneys, lungs, heart 
or pancreas (1). The onset of symptoms is 
often delayed, occurring 2–8 weeks after drug 
initiation (2). The occurrence of this syndrome 
is rare. DRESS syndrome is a potentially life-
threatening hypersensitivity reaction 
associated with a variety of medications, 
particularly anti-epileptic drugs (3). In a study 
by Ganeva, et al. (4) four cases of DRESS 
syndrome associated with the use of 
carbamazepine was reported. In this study the 
four cases had similar clinical manifestations: 
a maculopapular eruption progressing to 
exfoliative erythroderma, fever, and 
lymphadenopathy. Leukocytosis, atypical 
lymphocytes and liver injury (in 2 patients) 
were also observed. The importance of this 
syndrome and specifically the present case is 
that: 
 
1. DRESS syndrome is an idiosyncratic 
drug reaction and is not dependent on 
the dose of the drug (5). 
2. DRESS syndrome has been found to 
be the major cause of hospitalization 
for dermatologic complications in 
patients treated with anticonvulsants 
(4). 
3. Carbamazepine is one of the drugs 
that has been widely prescribed for 
epileptic patients, and its adverse side 
effects such as the DRESS syndrome 
needs to be studied. 
4. Despite the fact that some medications 
such as corticosteroids can reduce 
symptoms of delayed hypersensitivity 
reactions, the only way to treat these 
reactions is prompt withdrawal of the 
offending drug (5).  
 
Presentation  
A 17 year-old man presented with a seven-day 
history of pruritic and scaling maculopapular 
rash and erythroderma with associated 
periorbital, face and extremities edema, fever, 
and elevated serum level of transaminases was 
admitted at Loghman Hakim hospital in 
Tehran, Iran in December, 2015. He reported 
having, seven days prior to presentation, 
pruritic and scaling rash over his face and 
chest, which progressed to his extremities over 
the next days. He had a history of brain 
disorder from childhood compatible with 
encephalomalacia in the left temporal lobe due 
to an old ischemic lesion as shown in his brain 
MRI and suffered from epilepsy that began 12 
years ago. He had been treated with sodium-
valproate, which was tapered off and changed 
to carbamazepine 400mg twice a day from 5 
weeks prior to his present admission. He had 
mildly reduced verbal and reading skills since 
childhood. The patient had no other significant 
past medical history, drug hypersensitivity, or 
alcohol or other substance use. Review of 
systems was positive for a few productive 
coughs, a sore throat and fever and negative 
for chest pain, dyspnea, abdominal pain, 
nausea, vomiting and weight-loss.  
On examination, the patient was febrile to 
39.0°C with a heart rate of 104 beats/minute, 
respiratory rate of 18/minute, and blood 
pressure of 120/70mmHg. The patient’s 
general appearance was well and he was 
oriented. A fine exanthematous rash was noted 
on the face, chest, upper (Figure 1) and lower 
limbs (Figure 2) especially in distal areas 
without significant involvement of the oral 
mucosa, palms, or soles. He had periorbital 
edema that prevented him from opening his 
eyes well (Figure 3), which was a notable sign 
in this case. His abdomen was soft and non-
distended with no tenderness or 
hepatomegally. On neurological examination 
no focal deficits or other abnormal signs were 
detected. The differential diagnosis of the 
current presentation are drug-induced 
hypersensitivity, erythema multiforme, an 
exanthem caused by viral infections such as 
Epstein–Barr virus (EBV), cytomegalovirus 
(CMV) and human immunodeficiency virus 
(HIV), vasculitis and auto-immune diseases 
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Figure 2. Macular rash with erythroderma 
on the lower limbs. 
 
 
Figure 3. Periorbital edema with mild 
erythema. 
 
Laboratory findings revealed a white blood 
cell count of 7.6 thousand/mm3 (normal from 
4 to 10 thousand/mm3), with 65% neutrophils, 
27% lymphocytes, 4% eosinophils (absolute 
0.30 thousand/mm) and 3% monocytes. His 
basic metabolic lab tests were within normal 
limits. Liver function tests showed an aspartate 
aminotransferase (AST) of 149 U/L (normal 
from 0 to 37), and alanine aminotransferase 
(ALT) of 254 U/L (normal from 0 to 41). 
Also, blood cultures were measured twice, 
which were negative. Evaluations for viral 
hepatitis with serologies were negative for A, 
B and C types. HIV testing was negative. 
Screening for systemic lupus erythematous 
was done by measuring serum level of 
antinuclear antibodies (ANA), which was 
negative. We also requested cardiology 
consultation for investigation of probable 
cardiac disorders particularly myocarditis that 
was performed but ECG and echocardiography 
did not show any pathologic disorders. The 
patient was admitted with a diagnosis of drug-
induced hypersensitivity. Carbamazepine was 
discontinued and the patient was monitored for 
signs of clinical and laboratory improvement.  
On the first day of hospitalization, 
carbamazepine was discontinued and the 
patient’s periorbital and facial swelling 
deteriorated. Serum level of transaminases 
began to increase. A repeat complete blood 
count (CBC) showed eosinophilia at 8.0%. We 
started prednisolone 20mg orally two times 
daily to control his deteriorating condition. On 
the second day, a punch biopsy was taken 
from the skin of the forearm, which showed a 
vasculopathic lichenoid reaction pattern 
compatible with drug reaction (
 
Figure 4). On the third day, the patient showed 
a significant clinical recovery from swelling 
and the rashes were reduced. On the fourth day 
his levels of transaminases began to improve, 
and by day 9 his transaminases had greatly 
improved and prednisolone was tapered to 
30mg daily and he was discharged on 
prednisone 30 mg to be taken once a day until 
follow-up. After discontinuation of 
carbamazepine and the administration of 
prednisolone, the patient showed a dramatic 




Figure 4. A skin punch biopsy microscopic 
view showing a non-specific vasculopathic 
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DRESS syndrome can occur with any 
medication but the aromatic anticonvulsants 
(such as phenytoin, phenobarbital and 
carbamazepine) and sulphonamides are the 
most common causes of this syndrome (2, 3). 
Also, according to some case reports 
allopurinol (6) and dapsone (7) can cause this 
syndrome, too. The incidence is about one in 
1000 to one in 10,000 in reaction to drug (8) 
and has no age or sex tendency (9).  
The pathogenesis of DRESS syndrome is not 
completely clear. However, three potential 
factors have been found in its pathogenesis: 
first, a defect in a drug metabolism pathway 
that can lead to a failure of toxic reactive 
intermediates elimination, second, reactivation 
of human herpes virus 6 (HHV-6), human 
herpes virus 7 (HHV-7), Epstein-Barr virus 
(EBV), or cytomegalovirus (CMV), which 
may provoke the reaction, and third, genetic 
factors that affect immune responses (1, 8, 10, 
11). Vitamin D deficiency is a possible factor 
in the pathogenesis of DRESS due to its 
protective role against inflammatory and auto-
immune disorders, and because its deficiency 
is more common in people with darker skin 
phenotypes (12).  
The Severe Cutaneous Adverse Reactions 
(RegiSCAR) study group in 1996, Kardaun et 
al. (13), introduced a scoring system, which 
has been commonly used to evaluate potential 
cases of DRESS syndrome (table 1). The 
patient in this case report had a score of six 
points, indicating a ‘definite case’ (table 1). 
 
Table1. Patient’s score according to RegiSCAR scoring system. 
 
Patient’s Score Patient’s Data RegiSCAR Scoring System 
1 Fever: 39°C Fever: > 38.5°C  
0 No Lymphadenopathy. Enlarged lymph nodes 
1 Eosinophilia: 8% Eosinophilia 
0 Without atypical lymphocytosis. Atypical lymphocytosis 
1 A fine exanthematous rash was 
noted on the face, chest, upper and 
lower limbs. 
Skin involvement 
1 Liver involvement with presentation 
of elevated liver enzymes (AST: 
149 U/L, ALT: 254 U/L). 
Organ involvement 
1 Prolonged resolution about 3 weeks. Resolution: > 15 days 
1 ANA: Negative. 
Blood cultures at two times were 
negative.  
Evaluation for viral hepatitis with 
serologies was negative for A, B 
and C types.  
HIV testing was negative. 
Evaluation of other causes (ANA, 
blood cultures, serology for 
hepatitis A virus, hepatitis B virus, 
hepatitis C virus, and chlamydia 
and/or mycoplasma) 
Final Score of this Patient: 6 
(Definite case) 
Each of the components of this criteria has 1 score; 
A final score of: 
< 2 indicates no case,  
2-3 indicates a possible case,  
4-5 indicates a probable case,  
> 5 indicates a definite case. 
 
Cabrera Fundora EJ, et al. (14) reported a 
female patient under prescription for 
carbamazepine for trigeminal neuralgia who 
presented with skin lesions, which were 
initially attributed to a hypersensitivity 
reaction. The lesions worsened in spite of 
treatment and systemic symptoms ensued. A 
diagnosis of DRESS syndrome was proposed 
and steroid treatment was initiated with rapid 
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 our case and the response found to treatment 
with steroids were similar to the study by 
Cabrera Fundora EJ, et al (14).  
In managing severe hypersensitivity drug 
reactions the main treatment is the 
discontinuation of the probable causative drug. 
Therefore, the earlier the drug is withdrawn, 
the prognosis would be better. Systemic 
corticosteroids are traditionally prescribed in 
cases with severe conditions such as 
transaminases greater than five times normal, 
renal involvement, pneumonia, 
hemophagocytosis, or cardiac involvement. 
Other immune suppressants, such as 
cyclosporine, may also be required (15). In the 
absence of specific treatment, preventive 
measures have a key role in the management 
of DRESS syndrome (16).  
 
Conclusion  
The diagnosis of DRESS syndrome must be 
considered probable in patients with the 
following signs: skin rash, fever, hepatic 
involvement, eosinophilia and 
lymphadenopathy particularly when 
prescribing any anti-epileptic medication. 
Early diagnosis of DRESS syndrome is of 
great importance, since the mortality rate may 
be up to 10%. After the diagnosis there must 
be immediate intervention to control life-
threatening complications. Reactivation of 
HHV-6, is one of the potential causative 
factors in pathogenesis of DRESS syndrome. 
Thus, the French Society of Dermatology 
recommended the prescription of steroids with 
ganciclovir in patients with severe conditions 
who have a high level of viral reactivation of 
HHV-6 (17). Sufficient studies about DRESS 
syndrome using sensitive paradigms like 
randomized control trials (RCT) have not been 
done. Thus, further studies are needed to 
formulate new treatment guidelines for the 
present syndrome.  
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